TECHNOLOGY
The Business of Science: Why Data Strategy is Now a Boardroom Topic
This article highlights how scientific data strategy is becoming a boardroom priority in Indian biopharma, driving compliance, faster approvals, and global competitiveness through digitized lab systems and robust data infrastructure.
Mary Donlan, Ph.D., Executive Director, Product Marketing
Scientific data has quietly become one of the most powerful competitive drivers in India’s generics and biosimilars sector. As companies scale into regulated markets, the ability to generate, manage, and defend high-quality data is now shaping everything from regulatory success to global partnerships. What once lived in paper notebooks or scattered spreadsheets has become a boardroom concern, influencing market operation, reliability, and audit outcomes. When treated strategically, data shifts from being a record of past experiments to an asset that strengthens compliance, accelerates filings, and supports consistent, high-quality manufacturing across the product lifecycle.
Scientific Data as a Strategic Imperative for Indian Biopharma
In India’s life sciences industry, particularly in generics and biosimilars, success has traditionally depended on speed, regulatory compliance, and the capacity to operate at scale. What is now becoming clear is that the ability to generate, organize, manage, and act on scientific data is itself a strategic asset. When handled well, data becomes more than a by-product of lab work, it becomes a lever that can accelerate market entry and support global compliance. For instance, accurate tracking of batch records, stability studies or assay validation results can speed up regulatory approvals and time-to-market and ensure consistent product quality.
The data lifecycle, from initial discovery and analytical testing, through to stability studies and quality control, is now deeply connected to business outcomes. A robust laboratory management system helps ensure data integrity, traceability, and compliance with global standards, while also accelerating retrieval of information for audits or regulatory inspections. To illustrate, digital solutions offer automated linking of instrument data to experimental logs, digital signatures to confirm method approvals, and real-time dashboards to monitor deviations or out-of-spec results.
For Indian biopharma firms competing globally, the shift in management of scientific data has major implications. When labs rely on fragmented spreadsheets or manual record keeping, they risk delays and errors at audit. Digital solutions can centralize all data, automate workflows, and enforce audit trails, making audits smoother, quality controls faster, and methods more reproducible.
Thus, investing in modern data infrastructure is a chance to strengthen operations discipline, reduce rework, and shorten-go-to-market timelines without compromising quality. For companies operating in tight-margin generics or biosimilar markets, this can make the difference between being a low-cost supplier and globally trusted manufacturer.
The Business Value of Scientific Data in a Post-Patent World
In the generic and biosimilars space, Indian companies often work with molecules with long-expired patents. That, however, doesn’t mean the data has no value. On the contrary, robust, reliable lab data is now central to global competitiveness.
High-quality, audit-ready laboratory data reduces regulatory risk, supports global filings, and builds confidence among partners, Contract Research Organizations (CROs), and distributors. Regulatory agencies such as the Food and Drug Administration (FDA) explicitly define data integrity completeness, consistency and accuracy as a core requirement for submissions. Failures in data integrity, whether through gaps in documentation or an inability to trace how results were generated, have been directly linked to audit citations or even stalled or rejected regulatory submissions. Even minor inconsistencies in analytical method records or batch histories can delay approvals or trigger additional inspections.
Beyond regulatory compliance, data quality increases product workflow efficiency. For firms managing tech transfer and global operations, consistent and traceable data ensures reproducible processes and reliable product quality. For instance, documenting assay validations with linked instrument data, tracking deviations in formulation steps, and maintaining electronic batch records that integrate research and development (R&D) and Quality Control (QC) outputs all aid in maintaining consistently high product quality and yield. A recent peer-reviewed analysis of R&D Chemistry, Manufacturing and Controls (CMC) data practices underlines that whether for early-stage development or late-stage analytic control, companies need data that’s reliable, traceable and complete, because this data underpins both regulatory submissions and ongoing lifecycle management.
Thus, for Indian firms expanding globally, scientific data has become a tangible business asset. Companies that maintain robust data practices differentiate themselves for smoother global operations and stronger alliances.
The Case for Lab Digitization: From ELNs to Integrated Platforms
Traditionally, laboratory data has been fragmented across paper notebooks, spreadsheets, and disconnected Quality Assurance (QA) or QC systems. This siloed approach often complicates traceability, slows down retrieval of historical data, and increases the risk of errors or lost records. In some facilities, even basic tasks, such as locating the most recent version of an assay protocol or retrieving chromatographic data from an instrument, can take hours, creating unnecessary bottlenecks.
More recently, digital platforms, especially Electronic Lab Notebooks (ELNs) and integrated lab data solutions, have begun attracting attention beyond scientists. Senior leadership such as Chief Information Officers (CIOs), Chief Operating Officers (COOs), and Chief Financial Officers (CFOs) are recognizing that digitizing lab operations is not simply convenient but also a strategic business move. A well implemented ELN centralizes data, offers secure storage, and provides structured documentation and full audit trails, enabling better data integrity, compliance readiness, and greater operational resilience. For instance, digital platforms can automatically capture high pressure liquid chromatography (HPLC) chromatograms, link stability study results to batch records or embed approved templates for method development.
By automating routing documentation tasks and ensuring instrument outputs flow directly into structured records, digitized platforms reduce administrative burden and free scientists to focus on core R&D work. The result is improved performance throughout, including shorter cycle times for formulation, testing and quality control workflows.
Digitization also enhances cross-functional collaboration. With all data stored in a unified, secure environment, teams across the R&D, QA, regulatory and manufacturing functions can work on the same “single source of truth” eliminating version-control issues and reducing risk of miscommunication or data loss – a critical advantage when labs span multiple sites or geographies. For example, QC teams can instantly view updated R&D methods, or regulatory teams can extract complete audit trails without manual collation.
From this perspective, lab digitization becomes both a tech upgrade and an investment in business continuity, regulatory compliance, and cost-efficiency. For Indian biopharma and biotech firms aspiring to compete globally, deploying ELNs and integrated lab data systems can translate into faster timelines, smoother inspections, and more reliable operations across the value chain.
Strategic Impact for Generics and Biosimilars Development
In both generics and biosimilars manufacturing, scientific data has shifted from a supporting role to a key driver of business success. For biosimilars, the challenge lies in demonstrating similarity and consistency across analytical and clinical datasets. Every characterization study, stability assessment, and batch comparison must be tracible and fully auditable. Gaps in data can delay regulatory review and may even force developers to repeat parts of their compatibility work, adding significant time and cost. Strong digital traceability ensures that every data point generated during development remains connected across the product lifecycle, giving regulators and global partners confidence in the reliability of the evidence submitted.
Generics face a parallel challenge: speed. Approvals for Abbreviated New Drug Applications (ANDAs) in the US or marketing authorizations in the EU rely on clean, review-ready lab data. Missing records, inconsistent method documentation or fragmented data can extend review cycles or prompt inspection findings. Labs that maintain structured, version-controlled records can deliver data immediately for regulatory scrutiny, can better justify their results, and respond faster to information requests, ultimately shortening the path to market entry.
Centralized digital platforms are essential in achieving these outcomes. They standardize experimental and analytical methods across teams and sites, reducing variability and preventing errors. Tech transfer from R&D to manufacturing becomes faster and more reliable, as QC teams can replicate validated processes without guesswork. Real-time dashboards provide visibility into experimental progress, validation studies and submission readiness, allowing leadership and regulatory teams to address gaps proactively.
For Indian biopharma firms competing globally, digitized data capabilities translate into measurable advantages. Biosimilar developers can substantiate product similarity with confidence, whilst generics manufacturers gain faster approvals without compromising quality. Embedding structured, auditable digital practices into everyday lab work strengthens operational resilience, reduces rework, and accelerates product launch timelines, turning scientific data into a tangible strategic asset.
Data Strategy in Practice: A New Mindset for Indian Firms
Forward-thinking Indian pharma and biotech firms are increasingly treating scientific data with the same discipline and governance as financial records, prioritizing auditability and transparency even before the first filing. A growing number of organizations now assign dedicated ownership roles such as data stewards or digital compliance leads rather than leaving documentation quality to individual scientists. These industry trends parallel similar shifts observed globally, where labs using ELNs classify data as a long-term corporate asset rather than a transient experimental output.
By capturing all experiment metadata, instrument outputs, method versions, and approval signatures in a centralized ELN, firms create a reusable, traceable data reservoir. Data consolidation enables companies to repurpose the same data for multiple regulatory filings, tech transfers or global market submissions, minimizing duplications and accelerating timelines. For instance, when a stability study or batch assay is documented digitally, it can be referenced both in ANDA/ biosimilar applications or as part of ongoing lifecycle management without rerunning experiments or reforming records.
The transformation in digital workflow shifts data strategy beyond the bench, making it a cross-functional initiative driven at the C-suite level, by heads of R&D, QA, regulatory, and increasingly by CIOs, COOs, and CFOs. The engagement of senior stakeholders reflects a growing recognition that robust data infrastructure underpins regulatory readiness, audit preparedness, and long-term scalability.
As a result, firms adopting ELNs and integrating lab data systems benefit from improved operational discipline, reduced rework, faster tech transfer, simpler audits, and smoother global filings. In the generics and biosimilar space, where margin pressures, competitive pace and regulatory scrutiny are high, a data-orientated mindset can differentiate a company as a reliable globally ready manufacturer rather than just a low-cost supplier.
Conclusion: Data Infrastructure as a Growth Lever
As Indian biopharma firms increasingly target tightly regulated markets, their ability to scale safely and compliantly hinges on robust digital infrastructure, especially in the lab. A well-designed data backbone allows firms to maintain traceability across multiple sites and prepare audit-ready documentation efficiently. For example, cloud-based informatics platforms now enable automated data capture, integrated audit trails, and real-time access to batch and assay records, helping labs operate around the clock and maintain compliance.
Even in the absence of original IP, scientific data when properly collected and managed becomes a tangible asset. Digitized lab records enable companies to reuse stability studies, analytical results, and method validations across multiple regulatory filings or markets without redundant rework. This recycling approach significantly reduces cost and shortens time-to-market.
Moreover, by shifting data strategy from a lab-level task to a company-wide, board-level priority, firms embed data governance, quality control and compliance into their operating model. Senior leadership increasingly recognizes that data infrastructure underpins regulatory readiness, audit preparedness, and long-term salability, making it a core organizational asset.
In this light, data becomes a foundation for future growth. For Indian generics and biosimilar companies, embracing digital lab infrastructure can transform scientific diligence into commercial advantage. By doing so, they not only improve operational efficiency and compliance but position themselves as globally credible, reliable, and future-ready players.
